本文源自：金融界 作者：行情君 药明生物技术有限公司是全球领先的生物制剂服务供应商，提供全面、综合及高度定制的服务，包括从 发现、开发到生产生物制剂的全过程。公司在2016年在中国生物制剂研发市场占有48%的市场份额，已 与全球20大制药公司中的12家建立合作关系。 截至2024年年报，药明生物营业总收入186.75亿元、净利润33.56亿元。 8月19日，药明生物将披露2025财年中报。 8月1日，药明生物(02269)盘中下跌2.02%，截至13:25，报31.55元/股，成交9.0亿元。 ...

Core Viewpoint - WuXi Biologics (02269) experienced a 5.06% increase in stock price, reaching HKD 35.3 per share with a trading volume of HKD 1.924 billion [1] Company Overview - WuXi Biologics is a leading global provider of biologics services, offering comprehensive, integrated, and highly customized services throughout the entire process from discovery and development to production of biologics [1] - The company held a 48% market share in China's biologics R&D market in 2016 and has established partnerships with 12 out of the top 20 global pharmaceutical companies [1] Financial Performance - As of the 2024 annual report, WuXi Biologics reported total revenue of HKD 18.675 billion and a net profit of HKD 3.356 billion [1] Analyst Ratings - On July 29, Zhongtai International Securities upgraded the rating to "Buy" and raised the target price to HKD 37.2 [1] Upcoming Events - WuXi Biologics is scheduled to disclose its interim report for the fiscal year 2025 on August 19 [1]